7 JCI-accredited hospitals · 45+ hospitals & clinics · 90+ countries served · 24/7 multilingual support
Prof. Dr. Nur Olgun Pediatric Oncology · Acibadem Kent Hospital (Izmir)

Prof. Dr. Nur Olgun

✓ Medically verified profile
Pediatric Oncology · Acibadem Kent Hospital (Izmir)

Prof. Dr. Nur Olgun

Prof. Dr. Nur Olgun is a pediatric oncologist at Acibadem Kent Hospital (Izmir) in İzmir, Turkey. She evaluates and treats children with lymphoma, Wilms tumor, childhood brain tumors and rare tumors, and her research has focused on neuroblastoma. Dr. Olgun consults in Turkish and English and offers video consultations to international patients.

Medically verified profile 47+ years in medicineTurkish · EnglishVideo consultation available
Reach Dr. Olgun Consultation options Free · a coordinator and the doctor’s team reply within 24 hours · no obligation
Prof. Dr. Nur OlgunAccepting international patients
SpecialtyPediatric Oncology
ConsultationVideo · In person · Second opinion
Profile

About Prof. Dr. Nur Olgun

Prof. Dr. Nur Olgun is a pediatric oncologist at Acibadem Kent Hospital (Izmir) in İzmir, with more than 47 years in medicine. She provides care for children with lymphoma, rare tumors, childhood brain tumors and Wilms tumor. Her clinical work is centered on the evaluation and treatment of childhood cancers, and her published research has focused in particular on neuroblastoma.

Dr. Olgun graduated from Ege University Faculty of Medicine in 1979. She completed training in Child Health and Diseases at Dokuz Eylül University Faculty of Medicine in 1984 and in Pediatric Hematology and Oncology at the same faculty in 1998. At the Dokuz Eylül University, Oncology Institute she became Associate Professor Doctor in 1989 and Professor Doctor in 1995. From 1985 to 1992 she was a faculty member in the Department of Pediatric Oncology, Child Health and Diseases, at the Dokuz Eylül University, Faculty of Medicine. From 1992 to 2025 she served as a faculty member of the Dokuz Eylül University, Oncology Institute, where she was Institute Director from 2012 to 2024. Between 2022 and 2024 she was also Dean of the Dokuz Eylül University, Faculty of Medicine. She retired from the Oncology Institute in 2025 and joined Acıbadem Healthcare Services in the same year.

Clinical focus

Dr. Olgun evaluates and treats children with a range of solid and hematologic cancers. Her areas of expertise include lymphoma, Wilms tumor, childhood brain tumors and rare tumors of childhood. Care discussions are focused on the individual child’s diagnosis, prior treatment and current needs, and treatment planning takes place within a multidisciplinary pediatric oncology setting.

Her academic work has concentrated on neuroblastoma. She has co-authored studies on chemo-immunotherapy regimens in refractory or relapsed neuroblastoma, on dinutuximab beta combined with conventional chemotherapy in relapsed or refractory high-risk disease, on genetic and protein biomarkers in neuroblastoma, and on national treatment protocols of the Turkish Pediatric Oncology Group. Dr. Olgun is a member of the International Society of Paediatric Oncology (SIOP), the International Society of Paediatric Oncology Europe Neuroblastoma Group (SIOPEN), The Pediatric Oncology East and Mediterranean (POEM) Group, the Turkish Pediatric Oncology Group (TPOG) Association, the Turkish Medical Association, the Turkish Cancer Research and Fight Foundation, and the Turkish Cancer Research and Fight Institution Association, İzmir Branch.

How Dr. Olgun works with international patients

Dr. Olgun consults in Turkish and English, and interpreters can be arranged for families who speak other languages. Before a visit, the Acibadem international patient team coordinates the collection of prior medical reports, pathology results and imaging, arranges appointments and organizes the hospital visit. A first consultation typically covers the child’s history and symptoms, a review of existing imaging and previous treatments, a clinical examination and a discussion of the available options. Video consultation is available for international patients who wish to discuss their child’s case before traveling or who need follow-up from abroad.

Clinical focus

What Dr. Olgun treats and performs

Each item opens the condition or treatment page with the care pathway for international patients.

Background

Education, career and memberships

Education & training

Education

  • 1998Dokuz Eylül University Faculty of Medicine Pediatric Hematology and Oncology
  • 1995Dokuz Eylül University, Oncology Institute, Professor Doctor
  • 1989Dokuz Eylül University, Oncology Institute, Associate Professor Doctor
  • 1984Dokuz Eylül University Faculty of Medicine Child Health and Diseases
  • 1979Ege University Faculty of Medicine
Career

Professional Experience

  • 2025Acıbadem Healthcare Services
  • 2025Dokuz Eylül University, Oncology Institute, Retirement
  • 2022–2024Dokuz Eylül University, Faculty of Medicine, Dean
  • 2012–2024Dokuz Eylül University, Oncology Institute, Institute Director
  • 1992–2025Dokuz Eylül University, Oncology Institute, Faculty Member, Institute Director
  • 1985–1992Dokuz Eylül University, Faculty of Medicine, Child Health and Diseases, Department of Pediatric Oncology, Faculty Member
Memberships

Professional Memberships

  • Turkish Medical Association
  • International Society of Paediatric Oncology Europe Neuroblastoma Group (SIOPEN)
  • The Pediatric Oncology East and Mediterranean (POEM) Group
  • Turkish Pediatric Oncology Group (TPOG) Association
  • Turkish Cancer Research and Fight Foundation
  • International Society of Paediatric Oncology (SIOP)
  • Turkish Cancer Research and Fight Institution Association, İzmir Branch
Selected publications

Selected Publications

  • Assessment of Chemo-Immunotherapy Regimens in Patients with Refractory or Relapsed Neuroblastoma: A Systematic Review with Meta-Analysis of Critical Oncological Outcomes J Clin Med. 2025 Jan 31;14(3):934 Olgun N, Arayici ME, Kizmazoglu D, Cecen RE.
  • Investigation of YAP-1, OTX-2, and nestin protein expressions in neuroblastoma: a preliminary study. Ann Clin Transl Neurol. 2024 Aug;11(8):2153-2165. Kum Özşengezer S, Altun ZS, Sanlav G, Baran B, Kızmazoğlu D, Aktaş S, Keskinoğlu P, Olgun N.
  • Low Expression of CASP8 Could be a Prognostic Biomarker in Neuroblastoma Patients. J Child Neurol. 2024 Oct;39(11-12):386-394. Altun Z, Ceyhan M, Yuan H, Kizmazoglu D, Aktas S, Olgun N.
  • Whole-exome sequencing reveals genetic variants in low-risk and high-risk neuroblastoma Gene. 2023 Apr 15;860:147233. Altun Z, Yuan H, Baran B, Aktaş S, Sönmez EE, Küçük C, Olgun N.
  • The association between birth weight and the risk of neuroblastoma: a meta-analysis of observational studies involving 4,361,141 participants. Am J Cancer Res. 2023 Sep 15;13(9):3854-3863. Olgun HN, Arayici ME, Cecen RE, Basbinar Y, Ellidokuz H.
  • Comparing Tribbles Homolog 3 (TRIB3) Protein Expression Levels with Clinicopathological Characteristics and Survival Among Neuroblastoma Patient Clin Med Insights Oncol. 2023 Sep 19;17:11795549231199926. Baran B, Sanlav G, Kizmazoglu D, Kum Ozsengezer S, Aktas S, Altun Z, Olgun N.
  • Unraveling the Mystery: Next Generation Sequencing Sheds Light on Neuroblastoma Pathogenesis and Targeted Therapies Front Biosci (Landmark Ed). 2023 Aug 17;28(8):171. Aktas T, Kizmazoglu D, Aktas S, Erol A, Serinan E, Gokbayrak O, Ozdemir SM, Altun Z, Ozer E, Cecen E, Ince D, Olgun N.
  • Dinutuximab beta plus conventional chemotherapy for relapsed/refractory high-risk neuroblastoma: A single-center experience. Front Oncol. 2022 Dec 23;12:1041443 Olgun N, Cecen E, Ince D, Kizmazoglu D, Baysal B, Onal A, Ozdogan O, Guleryuz H, Cetingoz R, Demiral A, Olguner M, Celik A, Kamer S, Ozer E, Altun Z,
  • Treatment of high-risk neuroblastoma: National protocol results of the Turkish Pediatric Oncology Group. J Cancer Res Ther. 2017 Apr-Jun;13(2):284-290. Aksoylar S, Varan A, Vergin C, Hazar V, Akici F, Dagdemir A, Buyukavci M, Kebudi R, Kurucu N, Sevinir B, Unal E, Vural S, Guler E, Apak H, Oniz H, Kar
  • Experience of the Izmir Pediatric Oncology Group on Neuroblastoma: IPOG-NBL-92 Protocol. Pediatr Hematol Oncol. 2003 Apr-May;20(3):211-8. Olgun N, Kansoy S, Aksoylar S, Cetingul N, Vergin C, Oniz H, Sarialioglu F, Kantar M, Uysal K, Tuncyurek M, Kargi A, Aktas S, Bayol U, Karaca I, Arika
Good to Know

Frequently Asked Questions

Which childhood cancers does Dr. Olgun treat?
Dr. Olgun's areas of expertise include lymphoma, Wilms tumor, childhood brain tumors and rare tumors of childhood. Her published research has concentrated on neuroblastoma, including studies on chemo-immunotherapy in relapsed or refractory disease and on genetic biomarkers. Each child's treatment plan depends on the diagnosis, stage and previous treatment.
Where does Dr. Olgun see international patients?
Dr. Olgun practices at Acibadem Kent Hospital (Izmir) in İzmir, Turkey. She joined Acıbadem Healthcare Services in 2025 after retiring from the Dokuz Eylül University, Oncology Institute, where she had been a faculty member since 1992 and Institute Director from 2012 to 2024.
Which languages does Dr. Olgun speak with patients?
Dr. Olgun consults in Turkish and English. For families who speak other languages, the Acibadem international patient team can arrange an interpreter for the consultation and for communication during the hospital visit, so that questions about diagnosis and treatment options can be discussed clearly.
What should we send for a case review before traveling?
It is generally helpful to provide the child's medical reports, pathology results, laboratory findings, imaging studies such as MRI or CT with the written reports, and a summary of any previous treatments. The Acibadem international patient team coordinates the collection of these documents and arranges the appointment.
What is Dr. Olgun's training and academic background?
Dr. Olgun graduated from Ege University Faculty of Medicine in 1979 and trained in Child Health and Diseases and in Pediatric Hematology and Oncology at Dokuz Eylül University Faculty of Medicine. She became Professor Doctor at the Dokuz Eylül University, Oncology Institute in 1995 and served as Dean of the Faculty of Medicine from 2022 to 2024.
Is a video consultation with Dr. Olgun possible?
Yes. Dr. Olgun offers video consultations for international patients. This can be used to discuss a child's existing reports and imaging before traveling or for follow-up from abroad. The international patient team arranges the appointment and collects the relevant documents in advance so they can be reviewed during the call.
Patient Voices

What patients say about their Acibadem care

★★★★★From 2,400+ verified reviews across the Acibadem group
★★★★☆ Verified Patient

“My anaesthesia care exceeded every expectation I had. Dr. Olguner explained every step clearly and never rushed me. I am deeply grateful for everything.”

Ngozi U. · Rwanda May 2025
★★★★☆ Verified Patient

“We brought our child in for cancer treatment and the care was wonderful. Prof. Dr. Olgun answered all our worried questions without making us feel silly. The facilities were spotless and modern.”

Stefan I. · Bosnia and Herzegovina July 2025
Where

Hospitals

Treatments

Treatment guides

We’re With You at Every Step

How can we help you today?

We value your privacy We use essential cookies to run this site and, with your consent, analytics cookies to understand how it is used and improve it. You can accept, reject, or choose what to allow. See our Cookie Policy.